Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 10 » default
ESCI
Impact Factor
Blood and Lymphatic Cancer: Targets and Therapy
ISSN: 1179-9889
- View all (104)
- Volume 14, 2024 (3)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Archive: Volume 10, 2020
Review
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20
Published Date: 3 November 2020
Original Research
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5
Published Date: 24 August 2020